Our impact
By leveraging research, we accelerate the adoption of advanced cell and gene therapies for the benefit of patients. We support the industry to overcome barriers throughout the cell and gene therapy life cycle. To ensure the UK remains at the forefront of research and development, we help people to acquire new skills, organisations to establish new capabilities and policymakers to develop new perspectives.
Stats & Outcomes
- 9companies supported that are conducting clinical trials
- 70companies collaborated with on ATMP innovation (60% of which are UK SMEs)
- 127collaborative projects
- 21International commercial collaborators
- 27university and research institute collaborators
- £177min financing raised by our UK collaborators
2024/25 Cell and Gene Therapy Catapult outputs and outcomes
To advance the industry we collaborate with academia and researchers to increase the flow and speed of translation of promising research into new therapies and supporting technologies; industry, to bring down the cost of goods and increase the capacity to meet the upcoming demand for advanced therapies, and healthcare services, to increase access to clinical trials, uptake of approved products and bring down the cost of use.
The partnerships we have developed have helped to position the UK as a global leader in the development of advanced therapies. They continue to drive growth and investment in the development of advanced therapy medicinal products (ATMPs) and realise value for the UK economy.